OSR Health (OSRHW) Net Cash Flow Growth (1y) (2023 - 2026)
OSR Health (OSRHW) Net Cash Flow Growth (1y) (2023 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.97 Bn | 131.12 Bn | 2.84 Bn | 172.72% |
| 2 | Regeneron Pharmaceuticals | 85.15 Bn | 77.15 Bn | 3.93 Bn | 53.21% |
| 3 | Argenx Se | 62.84 Bn | 57.65 Bn | 1.37 Bn | - |
| 4 | Moderna | 55.74 Bn | 50.60 Bn | 52.00 Mn | 47.11% |
| 5 | BeOne Medicines | 41.53 Bn | 36.43 Bn | 1.53 Bn | 75.60% |
| 6 | Alnylam Pharmaceuticals | 31.60 Bn | 28.29 Bn | 992.69 Mn | -100.75% |
| 7 | BioNTech SE | 27.32 Bn | 8.93 Bn | 668.28 Mn | -2,045.25% |
| 8 | Royalty Pharma | 27.29 Bn | 26.45 Bn | - | 149.49% |
| 9 | Insmed | 26.99 Bn | 25.83 Bn | 358.27 Mn | -104.22% |
| 10 | OSR Health | 1.40 Mn | 20.39 Mn | 86,605.00 | 70.01% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -103.79% |
| Dec 31, 2025 | -812.67% |
| Sep 30, 2025 | 756.38% |
| Jun 30, 2025 | -2,118.83% |
| Mar 31, 2025 | 22,945.63% |
| Dec 31, 2024 | -11.26% |
| Sep 30, 2024 | -281.86% |
| Jun 30, 2024 | 98.45% |
| Mar 31, 2024 | -102.48% |
| Dec 31, 2023 | -176.41% |
| Sep 30, 2023 | 1,163.38% |
| Jun 30, 2023 | -701.61% |